Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30883901 | 1.00 | RAB9A (0.46) | RAB9AHTTLMNAMAPK1TUBB1 | |
| SCHEMBL3138296 | 0.84 | AMY1A (0.37) | RAB9AHTTLMNAMAPK1ALDH1A1 | |
| SCHEMBL1021384 | 0.81 | CA2 (0.48) | MAPK1TUBB1ALDH1A1PTGS2KDM4E | |
| SCHEMBL1023562 | 0.80 | HTT (0.46) | RAB9AHTTLMNAMAPK1TUBB1 | |
| SCHEMBL1021779 | 0.78 | ALOX15 (0.42) | RAB9ALMNAMAPK1ALDH1A1NPC1 | |
| SCHEMBL9250075 | 0.77 | EPHX2 (0.46) | — | |
| SCHEMBL4030548 | 0.76 | ALDH1A1 (0.44) | RAB9AHTTMAPK1ALDH1A1MEN1 | |
| SCHEMBL6142235 | 0.75 | CA12 (0.31) | — | |
| SCHEMBL28996996 | 0.73 | ACHE (0.35) | TUBB1ALDH1A1KDM4E | |
| SCHEMBL667921 | 0.73 | CES2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100548950-C | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2009-10-14 | — | — | CN | claimed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| CN-1759084-A | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2006-04-12 | — | — | CN | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | LES LABORATOIRES SERVIER (FR) | 2026-03-10 | — | — | US | disclosed |
| EP-4003989-B1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | SERVIER LAB (FR) | 2023-12-27 | — | — | EP | disclosed |
| US-20220363677-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | VERNALIS (R&D) LTD (GB) | 2022-11-17 | — | — | US | disclosed |
| EP-4003989-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | Les Laboratoires Servier (FR) | 2022-06-01 | — | — | EP | disclosed |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| WO-2021018858-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2021-02-04 | — | — | WO | disclosed |
| US-4914224-A | HIGH-SPEED RESPONSE, WIDE TEMPERATURE RANGE, CHIRAL SMECTIC PHASES | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1990-04-03 | — | — | US | disclosed |
| US-4911862-A | Aromatic carboxylic ester | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1990-03-27 | — | — | US | disclosed |
| EP-0341686-A2 | Novel halogen-containing ester compounds, and their intermediates, and method of producing the same as well as liquid crystal compositions containing the same and light switching elements | JAPAN ENERGY CORPORATION (JP) | 1989-11-15 | — | — | EP | disclosed |
| US-4818432-A | CHIRAL LIQUID CRYSTAL | CHISSO CORPORATION (JP) | 1989-04-04 | — | — | US | disclosed |
| EP-0243209-A2 | 3-Substituted biphenyl compound | Chisso Corporation (JP) | 1987-10-28 | — | — | EP | disclosed |
| EP-0231853-A2 | Optically active carboxylic acid derivatives and liquid crystalline compositions comprising them | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1987-08-12 | — | — | EP | disclosed |
| EP-0197677-A2 | Halogen-containing, optically active liquid crystal compound and liquid crystal composition containing same | Chisso Corporation (JP) | 1986-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | RAB9A 3324/4885HTT 501/4885LMNA 3807/4885 |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | BCOR, BCL2A1, BAK1 | RAB9A 3362/4885HTT 4455/4885LMNA 230/4885 |
| US-20220363677-A1 | 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER | BAK1, BCL2, BCL2A1 | RAB9A 3819/4885HTT 2422/4885LMNA 685/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | RAB9A 3831/4885HTT 4377/4885LMNA 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.